As shown in Table 4, the use of an insulin sensitizer (HR 1.3, 95% CI: 1.2–1.6) or an insulin secretagogue (HR 1.3, 95% CI: 1.1–1.5) as first antidiabetic medication dispensed was associated with a similar CRC risk. This evidence concerns the gene INS and colorectal carcinoma.